Diabetes Mellitus, Type 2 clinical trials

The registry lists 10,378 studies for Diabetes Mellitus, Type 2 across more than 10 countries. 1,410 are recruiting or about to start. 8,249 of them are mainly about Diabetes Mellitus, Type 2 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Diabetes Mellitus, Lipoatrophic too: 10,382 studies, 1,409 open.

ClinicalTrials.gov finds 12,048 studies for Diabetes Mellitus, Type 2. How that becomes 10,357 here

This page counts the studies the registry files under Diabetes Mellitus, Type 2, and those it files under no condition that list Diabetes Mellitus, Type 2themselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

12,048Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−4Filed under a narrower condition, counted on its own pageDiabetes Mellitus, Lipoatrophic 4
−262List Diabetes Mellitus, Type 2 as a condition, but the registry did not file them under itMost often written as “Type2 Diabetes” (56), “Type2 Diabetes Mellitus” (23), and “Type2Diabetes” (22). The registry filed them under other conditions only, most often Diabetes Mellitus (69) and Obesity (53).
−1,502Match it another way907 name it in the title, 19 in a keyword, and 576 by a synonym or other text the search reads.
10,280Counted here and found by its search244 of them list Diabetes Mellitus, Type 2 in their own words; the registry filed them under no condition.
+77
Counted here, but its search does not find them
The first 20 of 77.
10,357The count on this page

Get an email when these change. Save the Diabetes Mellitus, Type 2 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 6,913
Status unknown: 997
Recruiting: 882
Terminated: 494
Not yet recruiting: 439
Active, not recruiting: 331

Phase

Phase 3: 1,470
Phase 4: 1,220
Phase 1: 1,136
Phase 2: 1,045
Early Phase 1: 70

Where

United States: 3,304
China: 908
Canada: 756
Germany: 756
United Kingdom: 572
Denmark: 476

Who runs them

Novo Nordisk A/S (642) · AstraZeneca (333) · Eli Lilly and Company (236) · Sanofi (185) · Merck Sharp & Dohme LLC (181) · Boehringer Ingelheim (130) · GlaxoSmithKline (129) · Takeda (104)

What is being tested here

Drugs under test in Diabetes Mellitus, Type 2 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Semaglutide	34	57	154
Empagliflozin	18	26	123
Metformin	15	75	285
Dapagliflozin	15	52	171
Tirzepatide	7	17	42
Enavogliflozin	7	8	14
Zenagamtide	7	6	9
Pioglitazone	6	31	119
Elecoglipron	6	6	18
Liraglutide	5	46	150

Drug classes tested here GLP-1 receptor agonists 59 open · SGLT2 inhibitors 44 open · DPP-4 inhibitors 8 open · Angiotensin receptor blockers (ARBs) 5 open · Mineralocorticoid receptor antagonists (MRAs) 5 open

Coming up

129phase 3 studies under way

552studies finish main data collection within a year35 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension · Phase 3 · THPharm Corp.
Nov 2026Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia · Phase 3 · CMG Pharmaceutical Co. Ltd
Nov 2026A Study of BGM0504 in Participants With Type 2 Diabetes · Phase 3 · BrightGene Bio-Medical Technology Co., Ltd.
Nov 2026A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise · Phase 3 · BrightGene Bio-Medical Technology Co., Ltd.
Dec 2026Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes · Phase 3 · Qilu Pharmaceutical Co., Ltd.
Dec 2026A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy · Phase 3 · Boryung Pharmaceutical Co., Ltd
Dec 2026Semaglutide for Smoking Cessation in Patients With Diabetes · Phase 3 · Ottawa Heart Institute Research Corporation
Dec 2026Canagliflozin Targeting Vascular Inflammation · Phase 3 · Ottawa Heart Institute Research Corporation
Dec 2026Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin · Phase 3 · Celltrion
Dec 2026Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients · Phase 3 · Khyber Medical College, Peshawar

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger. 52 (6%) take children under 18. 29 (3%) are for women only and 5 (1%) for men only; 203 (23%) take healthy volunteers.

Recruiting studies that take each age, of 882
Age	Women	Men
10	29 (3%)	28 (3%)
18	571 (65%)	553 (63%)
30	704 (80%)	684 (78%)
40	768 (87%)	747 (85%)
50	793 (90%)	776 (88%)
65	778 (88%)	762 (86%)
75	609 (69%)	596 (68%)
85	416 (47%)	402 (46%)

Across all 10,378 studies, recruiting or not: 49% stop at 75 or younger and 23% at 65; 6% take children; 2% are for women only and 4% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetes Mellitus, Type 2 studies take

Of 525 phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	6 mo2–14 · 514 studies	5 mo2–11 · 452 studies	24 mo11–41 · 62 studies
Phase 1/2	28 mo22–71 · 41 studies	—	—
Phase 2	15 mo11–27 · 293 studies	13 mo9–18 · 194 studies	34 mo16–50 · 99 studies
Phase 2/3	22 mo13–31 · 32 studies	—	21 mo11–30 · 26 studies
Phase 3	20 mo14–30 · 525 studies	19 mo14–26 · 438 studies	31 mo16–47 · 87 studies
Phase 4	24 mo13–42 · 452 studies	19 mo12–28 · 132 studies	31 mo14–49 · 320 studies
Interventional, no phase	21 mo10–39 · 2,243 studies	16 mo6–29 · 177 studies	21 mo10–40 · 2,066 studies
Observational	32 mo17–63 · 602 studies	25 mo16–44 · 170 studies	35 mo17–96 · 432 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out